Awards - International Myeloma Society

International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Translational Research Grant Application


The International Myeloma Society and Paula and Rodger Riney Foundation are proud to announce a new initiative “IMS Translational Research Award”. We anticipate funding grants focused on translational research in the field of plasma cell dyscrasias.

Goal: To foster and support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of plasma cell disorder. Although focused on finding a cure for multiple myeloma, the areas of research for this program is broad. This award will also encourage interaction between institutions to enhance collaborative research.

Request for Application: Applicants should submit the research proposal by February 15, 2021. The funding period is expected to start around April 2021, but some flexibility may be allowed in the current climate.

Budget:The grant will be an award between $ 175,000 to $250,000 dollars including maximal allowable institutional overhead of 8%. This may include salary support, as well as laboratory supplies and services and travel allowance and a detailed budget justification will be required. Equipment purchase is not allowed unless a special justification is provided to confirm its essential requirement. Applicants may apply for a second year of funding which will be evaluated based on research progress and available funding.

Eligibility: Applicant must be a faculty or a scientist with an MD, and/or PhD, who is established as a researcher.  Applicants with research experience outside of the field of plasma cell malignancies, who wishes now to apply their knowledge to developing translational research efforts focused on myeloma are encouraged. Women and underrepresented minorities are particularly encouraged to apply. Applicants with prior experience in laboratory research are preferred, but previous laboratory experience is not required. The PI or Co-I should be an IMS member. The applicant should agree to acknowledge IMS and the Paula and Rodger Riney Foundation as the funding source in any publication or presentation resulting from this funding. The applicants should provide a progress report at 6 months and at the end of the funding year and respond to periodic surveys for IMS to track career progress. 

Research areas: Translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. The Translational Research is defined in its broadest sense to include molecular assays, imaging techniques, drugs, biological agents, and/or other methodologies applicable to the treatment of myeloma. The translational research projects may involve the use of any cellular, molecular, structural, biochemical, and/or genetic experimental approaches. By this definition, projects are permitted to move not only in the forward direction, toward clinical trials and studies in areas of prevention, early detection, treatment, and development of biomarkers, but also in the reverse direction, using human biospecimens, often from clinical trials, to study new phenomena, or to develop new targets and treatments based on results from human studies. The project must be focused on translational research that meets the definition provided above and results in clinical translation. Project must be dedicated to capitalizing on research opportunities that have the potential to change the current paradigm in the management of myeloma.

Application format:
The research proposal should be total of 5 pages including figures but not including references and should include the following details: Use 0.5 inch margins, single-spaced, Arial 11 font

 1. Specific Aims: (maximum 1 page)
 2. Research Plan:
      a.  Background & Significance
      b. Innovation
      c. Preliminary results
      d. Experimental Approach including methods and potential problems and solutions as well as statistical considerations.
3. References (25 maximum).

Moreover, the application should include the following additional information.

1. A statement of how the applicant meets the eligibility criteria and provide a rationale for how the research project will provide a translational endpoint (<200 words);
2. Applicant’s CV
3. A letter of support from the applicant’s institution (Home Institution PI) that details the anticipated path.
4. Budget and justification 

The deadline for submitting applications will be February 15th, 2021. Applications should be sent by email to Moira Luthin (adminassistant@myelomasociety.org)

 

Contact. For additional questions, please contact us at president@myelomasociety.org

Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic

As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.

Awards - International Myeloma Society

Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions

As a response to the current pandemic, the International Myeloma Society has developed the following Recommendations for anti-Covid-19 vaccination in patients with multiple myeloma (MM) and related conditions, AL amyloidosis and other monoclonal gammopathies of clinical significance. These recommendations will help guide vaccination decision for your patients with plasma cell disorder. Please follow as appropriate for your practice and patient needs as well as local conditions and governmental directions. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances


International Myeloma Society (IMS) Career Development Award Application

The deadline of the International Myeloma Society's Career Development Award has been extended to February 15, 2021.

The International Myeloma Society is proud to announce a new initiative “IMS Career Development Award”. The IMS anticipates funding grants for young investigators focused on research in the field of plasma cell dyscrasias.

Goal: To foster the development of an academic career of young scientists pursuing research in the field of plasma cell disorders and to promote the development of the next generation of leaders in this field.  This award will also encourage interaction between institutions to enhance collaborative research

Request for Application: Applicants should submit the research proposal by February 15, 2021.

Budget. The grant will be an award of up to $75,000 dollars including maximal allowable institutional overhead of 8%. This may include 1 year of salary support for the grantee, budget for visa status adjustment and travel allowance. Applicants may apply for a second year of funding which will be evaluated based on research progress and available funding. The grantee should have a letter of support from an identified mentor willing to host the applicant for the period of the award. It is expected that the hosting laboratory will cover expenses for research consumables, equipment, and animal costs, if proposed. The applicant, if funded will also receive a complementary IMS membership for 1 year.

Eligibility. Applicants must be junior faculty, fellow or scientist with an MD, PhD, or MD, PhD who have not yet established themselves as independent researchers and who plan to have a career in the field of plasma-cell dyscrasias. Women and underrepresented minorities are particularly encouraged to apply. Applicants should not yet have received NIH funding or its international equivalent. Applicants with prior experience in laboratory research are preferred, but previous laboratory experience is not required. The proposed research should be in a different laboratory than the home institution and either the PI of the home or host institution should be an IMS member. The applicant should agree to acknowledge IMS as the funding source in any publication or presentation resulting from this funding. The applicants should provide a progress report at the end of the funding year and respond to periodic surveys from IMS to track career progress.

Research areas. Basic and translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. Outcomes research and non-laboratory projects that do not require a stay abroad in a research laboratory do not qualify for full funding but may be considered to receive partial funding.

Application format:

The research proposal should be total of 5 pages including figures but not including references and should include the following details:  Use 0.5 inch margins, single-spaced, Arial 11 font

1. Specific Aims: (maximum 1 page)
2. Research Plan: 
    a. Background & Significance
    b. Innovation
    c. Preliminary results
    d. Experimental Approach including methods and potential problems and solutions as well as statistical considerations.

3. References (25 maximum).

Moreover, the application should include the following additional information.
1. A statement of how the applicant meets the eligibility criteria and provide a rationale for how the research project in the selected laboratory will foster the career of the applicant (<200 words); 
2. Applicant’s CV
3. A letter of support from the applicant’s institution (Home Institution PI) that details the anticipated career path.
4. A letter of support from the Principal Investigator of the hosting laboratory including a statement on mentorship, provision of research resources to allow and facilitate the conduct of the proposed research.
5. Hosting Institution’s Principal Investigator CV to reflect his/her qualification as a mentor.
6. Budget and justification 

The deadline for submitting applications will be February 15, 2021. Applications should be sent by email to Moira Luthin (adminassistant@myelomasociety.org)

Contact. For additional questions, please contact us at president@myelomasociety.org